EyePoint (EYPT) Részvény Árfolyam
EyePoint Árfolyam
Az árbevétel évi 17,5%-kal nőtt az elmúlt 19 évben 31,37 M USD-ra. A(z) EyePoint nettó árrés jelenleg -739,4%, csökkent a néhány évvel ezelőtti -158,1%-hoz képest.
EyePoint részvényár
EyePoint üzleti modell és részvényelemzés
Gyakran feltett kérdések a EyePoint részvényről
EyePoint Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The business model of EyePoint Pharmaceuticals Inc revolves around developing sustained-release drug delivery systems for the treatment of serious eye diseases. By utilizing its proprietary technologies, the company aims to improve patients' outcomes by providing long-lasting and targeted drug delivery options. EyePoint Pharmaceuticals Inc focuses on developing and commercializing products addressing unmet medical needs, ultimately enhancing the quality of life for individuals suffering from various eye conditions.
EyePoint Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of EyePoint Pharmaceuticals Inc in the market are Aerie Pharmaceuticals Inc and Ocular Therapeutix Inc.
EyePoint Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and commercializing innovative ophthalmic products. Founded in 1987, EyePoint has a rich history of advancing patient care in the field of ophthalmology. With a strong focus on sustained-release drug delivery systems, the company has successfully developed and received regulatory approvals for several cutting-edge ophthalmic treatments. EyePoint Pharmaceuticals Inc continues to thrive as a leading player in the industry, catering to the needs of patients worldwide. With its commitment to innovation and improving eye health, EyePoint Pharmaceuticals Inc has become a trusted name in the pharmaceutical sector.
EyePoint Pharmaceuticals Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative ophthalmic treatments, making a positive impact on patient care. EyePoint Pharmaceuticals Inc received FDA approval for its sustained-release intraocular implant, DEXYCU®, which is used for treating inflammation after cataract surgery. Additionally, the company gained FDA approval for YUTIQ®, a micro-insert used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. These milestones demonstrate EyePoint Pharmaceuticals Inc's commitment to advancing therapeutic options in the field of ophthalmology.
EyePoint Pharmaceuticals Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered, as well as Europe, specifically Germany, France, and the United Kingdom. Additionally, EyePoint Pharmaceuticals Inc has a presence in selected markets in Asia, including Japan. With its global reach, EyePoint Pharmaceuticals Inc aims to bring innovative ophthalmic products and therapies to patients worldwide.
EyePoint Pharmaceuticals Inc represents a strong commitment to improving patient outcomes through advanced ophthalmic therapeutic solutions. With a focus on innovation, the company is dedicated to developing and commercializing sustained-release drug delivery technologies. EyePoint Pharmaceuticals strives to address unmet medical needs and provide convenient treatment options to patients suffering from serious eye conditions. By leveraging its expertise and cutting-edge research, EyePoint Pharmaceuticals aims to enhance the quality of life for individuals worldwide.
19 elemző értékeli jelenleg a EyePoint részvényt: 13 vételt, 6 tartást és 0 eladást javasol. 2026-re az elemzők 1,72 M USD árbevételt és -2,52 USD EPS-t várnak a EyePoint esetében.
Az aktuális árfolyamon a EyePoint részvény 3,07 EUR (3,44 USD).
A EyePoint részvény (EYPT) 3 tőzsdén jegyzett, többek között: NASDAQ (EYPT), Frankfurt (PV3B.F), München (PV3B.MU).
EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that develops and markets innovative drugs for body tissues and eye diseases. The company's business model focuses on the development, manufacturing, and marketing of therapeutics for chronic eye diseases such as macular degeneration, diabetic retinopathy, and uveitis. EyePoint Pharmaceuticals specializes in strategic partnerships and collaborations with renowned pharmaceutical companies and global organizations. The company offers drug solutions such as Iluvien, used for the treatment of macular degeneration, and Yutiq, intended for chronic uveitis therapy. Iluvien is a steroid implant composed of a unique formulation of fluocinolone acetonide (FAc) and a biopolymer that slowly degrades during use. It has a unique ability to exert a sustained effect on eye disease, significantly reducing the need for repeated intravitreal injections. Iluvien is approved in Europe and Canada and has been submitted to the US Food and Drug Administration (FDA). Yutiq is a steroid implant developed for the treatment of chronic uveitis. It is implanted into the posterior chamber of the eye and releases the active ingredient triamcinolone acetonide (TAc) to reduce inflammation. Yutiq has been approved by the FDA and is currently available in the United States. In addition, EyePoint Pharmaceuticals also offers Dexpel, a technology platform for long-lasting surgical implants. This platform can be utilized in various medical fields such as oncology, orthopedics, and neurosurgery to control drug release, prolong treatment duration, and reduce the need for repeated injections. EyePoint Pharmaceuticals also pursues a diversification strategy to expand its product portfolio and create stable growth. This includes collaborating with other companies to provide technology solutions and services tailored to the needs of customers. Overall, the business model of EyePoint Pharmaceuticals aims to bring innovative drugs to the market that enable effective treatment of eye diseases and significantly improve patients' quality of life. The company relies on a combination of well-established and innovative technologies to control drug release and ensure optimal therapy.
A várható bevétele EyePoint 1,72 M USD. Ez az érték az aktuális pénzügyi adatokon alapul, és a vállalat üzleti teljesítményét tükrözi.
A várható nyeresége EyePoint -209,36 M USD. A nettó nyereség a vállalat nyereségességét tükrözi az összes költség levonása után.
A EyePoint ár/nyereség mutatója (P/E) jelenleg -1,37. A P/E mutató az aktuális részvényárat az egy részvényre jutó nyereséggel hasonlítja össze, és segít a befektetőknek a EyePoint részvény értékelésének megértésében.
A EyePoint ár/értékesítés mutatója (P/S) jelenleg 166,45. A P/S mutató a piaci kapitalizációt az éves bevételhez hasonlítja, és a EyePoint részvény értékelési mérőszámaként szolgál.
Az Eulerpool minőségi pontszáma a EyePoint számára 2/10.
A EyePoint ISIN-je US30233G2093. Az ISIN (International Securities Identification Number) a nemzetközi securities azonosító.
A EyePoint WKN-je A2QJRU. A WKN (Wertpapierkennnummer) egy hatjegyű német értékpapír-azonosító szám.
A EyePoint ticker-e EYPT. A ticker szimbólum a EyePoint részvény tőzsdei kereskedésénél használatos.
EyePoint részvény
EyePoint Peer Group
EyePoint Tőzsdei rövidítés
EyePoint FIGI
A EyePoint összes alapfundamentuma és mélyreható elemzése
A EyePoint részvény Eulerpool-elemzése olyan fontos pénzügyi mutatókat tartalmaz, mint a bevétel, nyereség, P/E arány, P/S arány, EBIT, valamint információk az osztalékról. Vizsgáljuk a részvények, piaci kapitalizáció, adósság, saját tőke és kötelezettségek vonatkozásait is EyePoint. Ha részletesebb információt keres ezekről a témákról, részletes elemzéseket kínálunk az aloldalainkon.